172 related articles for article (PubMed ID: 24138765)
1. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011.
Schmidt MA; Gold R; Kurosky SK; Daley MF; Irving SA; Gee J; Naleway AL
J Adolesc Health; 2013 Nov; 53(5):637-41. PubMed ID: 24138765
[TBL] [Abstract][Full Text] [Related]
2. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
4. Factors predicting completion of the human papillomavirus vaccine series.
Gold R; Naleway A; Riedlinger K
J Adolesc Health; 2013 Apr; 52(4):427-32. PubMed ID: 23298984
[TBL] [Abstract][Full Text] [Related]
5. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.
Stokley S; Jeyarajah J; Yankey D; Cano M; Gee J; Roark J; Curtis RC; Markowitz L; ;
MMWR Morb Mortal Wkly Rep; 2014 Jul; 63(29):620-4. PubMed ID: 25055185
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Jul; 62(29):591-5. PubMed ID: 23884346
[TBL] [Abstract][Full Text] [Related]
8. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
[TBL] [Abstract][Full Text] [Related]
9. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series.
Harper DM; Verdenius I; Harris GD; Barnett AL; Rosemergey BE; Arey AM; Wall J; Malnar GJ
Prev Med; 2014 Apr; 61():20-5. PubMed ID: 24440159
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Chesson HW; Curtis CR; Gee J; Bocchini JA; Unger ER;
MMWR Recomm Rep; 2014 Aug; 63(RR-05):1-30. PubMed ID: 25167164
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
Geier DA; Geier MR
Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
[TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus Infection and Vaccination.
Valentino K; Poronsky CB
J Pediatr Nurs; 2016; 31(2):e155-66. PubMed ID: 26586310
[TBL] [Abstract][Full Text] [Related]
13. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
[TBL] [Abstract][Full Text] [Related]
14. Quantifying clinical HPV4 dose inefficiencies in a safety net population.
Harper DM; Verdenius I; Ratnaraj F; Arey AM; Rosemergey B; Malnar GJ; Wall J
PLoS One; 2013; 8(11):e77961. PubMed ID: 24223131
[TBL] [Abstract][Full Text] [Related]
15. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
Vetter KM; Geller SE
J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
Gee J; Naleway A; Shui I; Baggs J; Yin R; Li R; Kulldorff M; Lewis E; Fireman B; Daley MF; Klein NP; Weintraub ES
Vaccine; 2011 Oct; 29(46):8279-84. PubMed ID: 21907257
[TBL] [Abstract][Full Text] [Related]
19. An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010.
Laz TH; Rahman M; Berenson AB
Vaccine; 2012 May; 30(24):3534-40. PubMed ID: 22480927
[TBL] [Abstract][Full Text] [Related]
20. Long-term study of a quadrivalent human papillomavirus vaccine.
Ferris D; Samakoses R; Block SL; Lazcano-Ponce E; Restrepo JA; Reisinger KS; Mehlsen J; Chatterjee A; Iversen OE; Sings HL; Shou Q; Sausser TA; Saah A
Pediatrics; 2014 Sep; 134(3):e657-65. PubMed ID: 25136050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
